The Genetics of Warfarin Dose-Response Variability in Africans: An Expert Perspective on Past, Present, and Future

OMICS A Journal of Integrative Biology

Volumn 23, Issue 3, 2019, Pages 152-166

  Ndadza, Arinao ^a   Thomford, Nicholas Ekow ^a   Mukanganyama, Stanley ^b   Wonkam, Ambroise ^a   Ntsekhe, Mpiko ^a   Dandara, Collet ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF ZIMBABWE   (Zimbabwe)

Author keywords

Africa; anticoagulation; CYP2C9; Global pharmacogenetics; VKORC1; warfarin

Indexed keywords

APOLIPOPROTEIN E; CYTOCHROME P450 2C9; CYTOCHROME P450 FAMILY 2; WARFARIN; ANTICOAGULANT AGENT;

AFRICAN; ALLELE; ARTICLE; BOTSWANA; DOSE RESPONSE; DRUG INDICATION; DRUG METABOLISM; EGYPT; ETHIOPIA; GENETIC VARIABILITY; GHANA; HUMAN; KENYA; MOZAMBIQUE; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; SOUTH AFRICA; SUDAN; TANZANIA; AFRICA; GENE FREQUENCY; GENETICS; GENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICA; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE FREQUENCY; GENOTYPE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 85063135897     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2019.0018     Document Type: Article

References (120)

1. Abdelhedi R, Bouayed NA, Alfadhli S, Abid L, Rebai A, and Kharrat N. (2015). Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations. J Genet 94, 765-770.
2. Adehin A, Bolaji OO, and Kennedy MA. (2017). Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population. Drug Metab Pharmacokinet 32, 189-191.
3. Afilal D, Basselam MA, Brakez Z, Chouham S, Brehm A, and Izaabel EH. (2017). Genetic polymorphism of drug-metabolizing enzymes CYP2C9 and CYP2C19 in Moroccan population. Genet Test Mol Biomarkers 21, 298-304.
4. Ahmed NO, Osman B, Abdelhai YM, and El-Hadiyah TMH. (2017). Impact of clinical pharmacist intervention in anticoagulation clinic in Sudan. Int J Clin Pharm 39, 769-773.
5. Aithal GP, Day CP, Kesteven PJ, and Daly AK. (1999). Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719.
6. Alessandrini M, Asfaha S, Dodgen TM, Warnich L, and Pepper MS. (2013). Cytochrome P450 pharmacogenetics in African populations. Drug Metab Rev 45, 253-275.
7. Allabi AC, Gala J, and Horsmans Y. (2005). CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 15, 779-786.
8. Alzubiedi S, and Saleh M. (2016). Pharmacogenetic-guided Warfarin Dosing Algorithm in African-Americans. J Cardiovasc Pharmacol Ther 67, 86-92.
9. Awolesi D, Naidoo M, and Cassimjee MH. (2016). The profile and frequency of known risk factors or comorbidities for deep vein thrombosis in an urban district hospital in KwaZulu-Natal. South Afr J HIV Med 17, 425.
10. Bauersachs R. (2016). Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism. Thromb Res 144, 12-20.
11. Bazan N, Sabry N, Rizk A, Mokhtar S, and Badary O. (2012). Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients. Int J Clin Pharm 34, 837-844.
12. Bazan N, Sabry N, Rizk A, Mokhtar S, and Badary O. (2014). Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: Role of gene polymorphism. Ir J Med Sci 183, 161-172.
13. Bechtold U, Fuchs D, and Gudowsky N. (2017). Imagining socio-technical futures-Challenges and opportunities for technology assessment. JRI 4, 85-99.
14. Booth SL. (2010). Dietary vitamin K guidance: An effective strategy for stable control of oral anticoagulation. Nutr Rev 68, 178-181.
15. Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, and Cavallari LH. (2012). Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics 13, 1925-1935.
16. Bungard TJ, Yakiwchuk E, Foisy M, and Brocklebank C. (2011). Drug interactions involving warfarin: Practice tool and practical management tips. Can Pharm J 144, 25.e9.
17. Caldwell MD, Awad T, Johnson JA, et al. (2008). CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112.
18. Cavallari LH, Langaee TY, Momary KM, et al. (2010). Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 87, 459-464.
19. Cavallari LH, and Perera MA. (2012). The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol 8, 563-576.
20. Cavallari LH, Perera M, Wadelius M, et al. (2012). Association of the GGCX (CAA) 16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics 22, 152.
21. Chen W, Wu L, and Liu X. (2017). Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement. Int J Clin Pharmacol Ther 55, 126-132.
22. Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris SA, and Ramsay M. (2011). Genetic variants in CYP (-1A2,-2C9,-2C19,-3A4 and-3A5), VKORC1 and ABCB1 genes in a black South African population: A window into diversity. Pharmacogenomics 12, 1663-1670.
23. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. (2005). A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649.
24. Daneshjou R, Gamazon ER, Burkley B, et al. (2014). Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood 124, 2298-2305.
25. Danwang C, Temgoua MN, Agbor VN, Tankeu AT, and Noubiap JJ. (2017). Epidemiology of venous thromboembolism in Africa: A systematic review. J Thromb Haemost 15, 1770-1781.
26. Dean L. (2016). Warfarin therapy and the genotypes CYP2C9 and VKORC1. March 8, 2012 [Updated June 8, 2016]. In: Pratt V, McLeod H, Dean L, et al., eds. Medical Genetics Summaries (Internet). Bethesda, MD: National Center for Biotechnology Information.
27. de Boer B, Hoek J, and Kudina O. (2018). Can the technological mediation approach improve technology assessment? A critical view from "within." JRI 5, 299-315.
28. Dickmann LJ, Rettie AE, Kneller MB, et al. (2001). Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 60, 382-387.
29. Ebrahim I, Bryer A, Cohen K, Mouton JP, Msemburi W, and Blockman M. (2018). Poor anticoagulation control in patients taking warfarin at a tertiary and district-level prothrombin clinic in Cape Town, South Africa. S Afr Med J 108, 490-494.
30. Ekladious S, Issac M, Sharaf S, and Abou-Youssef H. (2013). Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients. Mol Diagn Ther 17, 381-390.
31. El-Din MK, Farhan MS, El Shiha RI, El-Kaffas RMH, and Mousa SM. (2014). Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients. Pediatr Drugs 16, 337-341.
32. El-Din MS, Amin DG, Ragab SB, Ashour EE, Mohamed MH, and Mohamed AM. (2012). Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: Proposal for a new dosing regimen. Int J Lab Hematol 34, 517-524.
33. Fenta TG, Assefa T, and Alemayehu B. (2017). Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia: A retrospective cross-sectional study. BMC Health Serv Res 17, 389.
34. Finkelman BS, Gage BF, Johnson JA, Brensinger CM, and Kimmel SE. (2011). Genetic warfarin dosing. J Am Coll Cardiol 57, 612-618.
35. Gage B, Eby C, Johnson J, et al. (2008). Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84, 326-331.
36. Gage BF, and Lesko LJ. (2008). Pharmacogenetics of warfarin: Regulatory, scientific, and clinical issues. J Thromb Thrombolysis 25, 45-51.
37. Ghozlan M, Foad D, Darwish Y, and Saad A. (2015). Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome. Blood Coagul Fibrinolysis 26, 499-504.
38. Greenblatt DJ, and Moltke LL. (2005). Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 45, 127-132.
39. Hafner Jr JW, Belknap SM, Squillante MD, and Bucheit KA. (2002). Adverse drug events in emergency department patients. Ann Emerg Med 39, 258-267.
40. Hamadeh IS, Shahin MH, Lima SM, et al. (2016). Impact of GGCX, STX1B and FPGS polymorphisms on warfarin dose requirements in European-Americans and Egyptians. Clin Transl Sci 9, 36-42.
41. Harrington AR, Armstrong EP, Nolan Jr PE, and Malone DC. (2013). Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 44, 1676-1681.
42. Hellenbart EL, Faulkenberg KD, and Finks SW. (2017). Evaluation of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag 13, 325.
43. Hirsh J, Dalen JE, Anderson DR, et al. (1998). Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114, 445S-469S.
44. Issac MSM, El-Nahid MS, and Wissa MY. (2014). Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? A study on a cohort of the Egyptian population. Mol Diagn Ther 18, 73-83.
45. Jacobs A, Decloedt EH, and Bassa F. (2017). A preliminary review of warfarin toxicity in a tertiary hospital in Cape Town, South Africa. Cardiovasc J Afr 28, 346.
46. James AH, Britt RP, Raskino CL, and Thompson SG. (1992). Factors affecting the maintenance dose of warfarin. J Clin Pathol 45, 704-706.
47. Janha RE, Sisay-Joof F, Hamid-Adiamoh M, et al. (2009). Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. Pharmacogenomics 10, 1423-1431.
48. Jiang X, Williams KM, Liauw WS, et al. (2004). Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 57, 592-599.
49. Johnson J, Caudle K, Gong L, et al. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 Update. Clin Pharmacol Ther 102, 397-404.
50. Johnson MA. (2005). Influence of vitamin K on anticoagulant therapy depends on vitamin K status and the source and chemical forms of vitamin K. Nutr Rev 63, 91-97.
51. Jonas DE, and McLeod HL. (2009). Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 30, 375-386.
52. Jorgensen AL, Al-Zubiedi S, Zhang JE, et al. (2009). Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: A prospective study. Pharmacogenet Genomics 19, 800.
53. Juurlink DN. (2007). Drug interactions with warfarin: What clinicians need to know. Can Med Assoc J 177, 369-371.
54. Kamali F, Khan TI, King BP, et al. (2004). Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75, 204-212.
55. Kaminsky LS, and Zhang ZY. (1997). Human P450 metabolism of warfarin. Pharmacol Ther 73, 67-74.
56. Kanyi J, Karwa R, Pastakia SD, Manji I, Manyara S, and Saina C. (2017). Venous thromboembolism requiring extended anticoagulation among HIV-Infected patients in a rural, resource-constrained setting in Western Kenya. Ann Pharmacother 51, 380-387.
57. Kimmel SE. (2008). Warfarin therapy: In need of improvement after all these years. Expert Opin Pharmacother 9, 677-686.
58. Kimmel SE, French B, Kasner SE, et al. (2013). A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369, 2283.
59. Kimmel SE, Christie J, Kealey C, et al. (2008). Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics 8, 53.
60. Kou H, Ma R, Gao D, Zhu C, and Zheng Q. (2017). GW28-e1078 study of CYP2C9 and VKORC1 gene polymorphism on warfarin steady-state therapeutic dose and individual anticoagulation effect. J Am Coll Cardiol 70, C135.
61. Kudzi W, Ahorhorlu SY, Dzudzor B, Olayemi E, Nartey ET, and Asmah RH. (2016). Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population. BMC Res Notes 9, 507.
62. Kudzi W, Dodoo AN, and Mills JJ. (2009). Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 10, 124.
63. Laäs DJ, and Naidoo M. (2018). An evaluation of warfarin use at an urban district-level hospital in KwaZulu-Natal Province, South Africa. S Afr Med J 108, 1046-1050.
64. Lee S, Ng S, Oldenburg J, et al. (2006). Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 79, 197-205.
65. Lewis BC, Nair PC, Heran SS, et al. (2016). Warfarin resistance associated with genetic polymorphism of VKORC1: Linking clinical response to molecular mechanism using computational modeling. Pharmacogenet Genomics 26, 44-50.
66. Limdi NA, Beasley TM, Crowley MR, et al. (2008). VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9, 1445-1458.
67. Limdi NA, Brown TM, Yan Q, et al. (2015). Race influences warfarin dose changes associated with genetic factors. Blood 126, 539-545.
68. Limdi NA, Wadelius M, Cavallari L, et al. (2010). Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across three racial groups. Blood 115, 3827-3834.
69. Louw S, Mayne ES, and Wan YO. (2018). Validation of the Mission® PT Coagulation Monitoring point-of-care device for the outpatient management of patients on long-term warfarin therapy. Int J Lab Hematol. 40, e71-e73.
70. Luis JR, Rowold DJ, Regueiro M, et al. (2004). The Levant versus the Horn of Africa: Evidence for bidirectional corridors of human migrations. Am J Hum Genet 74, 532-544.
71. Manji I, Pastakia SD DO AN, et al. (2011). Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya. J Thromb Haemost 9, 2215-2220.
72. Mariita K, Nyamu DG, Maina CK, Karimi PN, and Menge TB. (2016). Patient factors impacting on oral anticoagulation therapy among adult outpatients in a Kenyan referral hospital. Afr J Pharm Pharmacol 5, 193-200.
73. Mbokota N, Schapkaitz E, and Louw S. (2018). Verification of the qLabs international normalized ratio point-of-care device for monitoring of patients attending an anticoagulation clinic. Int J Lab Hematol. 40, 508-514.
74. Militaru FC, Vesa SC, Pop TR, and Buzoianu AD (2015). Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life 8, 171.
75. Mitchell C, Gregersen N, and Krause A. (2011). Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 12, 953-963.
76. Motshoge T, Tawe L, Muthoga CW, et al. (2016). Cytochrome P450 2C8*2 allele in Botswana: Human genetic diversity and public health implications. Acta Trop 157, 54-58.
77. Moualla H, and Garcia D. (2011). Vitamin K antagonists-Current concepts and challenges. Thromb Res 128, 210-215.
78. Muszkat M, Blotnik S, Elami A, Krasilnikov I, and Caraco Y. (2007). Warfarin metabolism and anticoagulant effect: A prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clin Ther 29, 427-437.
79. Mwita JC, Francis JM, Oyekunle AA, Gaenamong M, Goepamang M, and Magafu MG. (2018). Quality of anticoagulation with warfarin at a Tertiary Hospital in Botswana. Clin Appl Thromb Hemost 24, 596-601.
80. Ndadza A, Cindi Z, Makambwa E, et al. (2019). Warfarin dose and CYP2C gene cluster: An African Ancestral-specific variant is a strong predictor of dose in Black South African Patients. OMICS 23, 36.
81. Nguyen TN, Hilmer SN, and Cumming RG. (2013). Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol 167, 2412-2420.
82. Njovane XW, Fasinu PS, and Rosenkranz B. (2013). Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area. Cardiovasc J Afr 24, 19.
83. Oliveira E, Pereira R, Amorim A, McLeod H, and Prata MJ. (2009). Patterns of pharmacogenetic diversity in African populations: Role of ancient and recent history. Pharmacogenomics 10, 1413-1422.
84. Orsi FA, Bizzacchi JMA, De Paula EV, Ozelo MC, Langley MR, and Weck KE. (2010). VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. Thromb Res 126, e206-e210.
85. Ozer N, Cam N, Tangurek B, et al. (2010). The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Heart Vessels 25, 155-162.
86. Perera MA, Cavallari LH, and Johnson JA. (2014). Warfarin pharmacogenetics: An illustration of the importance of studies in minority populations. Clin Pharmacol Ther 95, 242-244.
87. Perera MA, Cavallari LH, Limdi NA, et al. (2013). Genetic variants associated with warfarin dose in African-American individuals: A genome-wide association study. Lancet 382, 790-796.
88. Perera MA, Gamazon E, Cavallari LH, et al. (2011). The missing association: Sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 89, 408-415.
89. Pirmohamed M, Burnside G, Eriksson N, et al. (2013). A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 369, 2294.
90. Ramirez AH, Shi Y, Schildcrout JS, et al. (2012). Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 13, 407-418.
91. Ramsay M. (2012). Africa: Continent of genome contrasts with implications for biomedical research and health. FEBS Lett 586, 2813-2819.
92. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, et al. (1992). Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Research Toxicol 5, 54-59.
93. Rieder MJ, Reiner AP, Gage BF, et al. (2005). Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352, 2285-2293.
94. Rost S, Fregin A, Oldenburg J, et al. (2004). Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541.
95. Rotimi CN, Bentley AR, Doumatey AP, Chen G, Shriner D, and Adeyemo A. (2017). The genomic landscape of African populations in health and disease. Hum Mol Genet 26, R236.
96. Röwer S, Bienzle U, Weise A, et al. (2005). High prevalence of the cytochrome P4502C8*2 mutation in Northern Ghana. Trop Med Int Health 10, 1271-1273.
97. Schapkaitz E, Louw S, Friedman J, Sithole J, Masebe M, and Jacobson BF. (2018). Conservative management of overanticoagulation in patients with low-moderate risk for bleeding complications. Clin Appl Thromb Hemost 24, 1255-1260.
98. Schapkaitz E, and Sithole J. (2017). Predictors of warfarin dose requirements in South African patients attending an anticoagulation clinic. J Vasc Nurs 35, 27-30.
99. Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, and Kimmel SE. (2010). New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol 70, 393-399.
100. Schelleman H, Chen Z., Kealey C, et al. (2007). Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther 81, 742-747.
101. Sconce EA, Khan TI, Wynne HA, et al. (2005). The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 106, 2329-2333.
102. Scordo MG, Aklillu E, Yasar U, Dahl M, Spina E, and Ingelman-Sundberg M. (2001). Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52, 447-450.
103. Scott SA, Edelmann L, Kornreich R, and Desnick RJ. (2008). Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 82, 495-500.
104. Shah A, Shewale A, Hayes CJ, and Martin BC. (2016). Cost-effectiveness of oral anticoagulants for ischemic stroke prophylaxis among nonvalvular atrial fibrillation patients. Stroke 47, 1555-1561.
105. Shahin MHA, Cavallari LH, Perera MA, et al. (2013). VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thromb Haemost 109, 1045.
106. Shahin MHA, Khalifa SI, Gong Y, et al. (2011). Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics 21, 130.
107. Shrif N, Won H, Lee S, et al. (2011). Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol 67, 1119-1130.
108. Sominsky S, Korostishevsky M, Kurnik D, et al. (2014). The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations. J Appl Genet 55, 163-171.
109. Sonuga BO, Hellenberg DA, Cupido CS, and Jaeger C. (2016). Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa. Afr J Prim Health Care Fam Med 8, e8.
110. Stambler BS, and Ngunga LM. (2015). Atrial fibrillation in Sub-Saharan Africa: Epidemiology, unmet needs, and treatment options. Int J Gen Med 8, 231-242.
111. Takahashi H, Wilkinson GR, Nutescu EA, et al. (2006). Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16, 101-110.
112. Tarus NK, Pau AK, Sereti I, et al. (2013). Challenges in management of warfarin anti-coagulation in advanced HIV/AIDS patients with venous thrombotic events-A case series from a research clinic in rural Kericho, Kenya. East Afr Med J 90, 207.
113. The International Warfarin Pharmacogenetics Consortium. (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360, 753-764.
114. Tishkoff SA, Reed FA, Friedlaender FR, et al. (2009). The genetic structure and history of Africans and African Americans. Science 324, 1035-1044.
115. Vargens DD, Damasceno A, Petzl-Erler ML, and Suarez-Kurtz G. (2011). Letter to the Editor: Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and Brazilians. Pharmacogenomics 12, 769-772.
116. Veenstra DL, You JH, Rieder MJ, et al. (2005). Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 15, 687-691.
117. Voora D, Koboldt DC, King CR, et al. (2010). A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 87, 445-451.
118. Wadelius M, Chen LY, Lindh JD, et al. (2009). The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113, 784-792.
119. Wadelius M, and Pirmohamed M. (2007). Pharmacogenetics of warfarin: Current status and future challenges. Pharmacogenomics J 7, 99-111.
120. Zhang X, Li L, Ding X, and Kaminsky LS. (2011). Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab Dispos 39, 1433-1439.